Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Invest New Drugs

Search In Journal Title:

Abbravation: Investigational New Drugs

Search In Journal Abbravation:

Publisher

Springer US

Search In Publisher:

DOI

10.1002/jps.2600541012

Search In DOI:

ISSN

1573-0646

Search In ISSN:
Search In Title Of Papers:

ZJU6 a novel derivative of Erianin shows potent

Authors: Frankie Lam Tracey D Bradshaw Hui Mao Scott Roberts Yuanjiang Pan Shudong Wang
Publish Date: 2011/10/14
Volume: 30, Issue: 5, Pages: 1899-1907
PDF Link

Abstract

ZJU6 was designed to enhance antiangiogenesis and antitumour activity of its parent compound Erianin a clinic antitumour agent This study investigated the detailed biological mechanism of ZJU6 in comparison with that of Erianin Both ZJU6 and Erianin substantially reduced cell viability and induced apoptosis in human cancer cell lines Profound G2/M cell arrest was observed 24 h after treatment of MCF7 cells with ZJU6 ≥ 25 μM or Erianin ≥ 01 μM being consistent with mitotic collapse 05 μM of Erianin or ZJU6 failed to stabilise tubulin PreG1 MCF7 cell accumulating 24 h post treatment indicated apoptosis Caspase3 activity PARP cleavage and Annexin V + ve /PI ve populations correlate the apoptotic destiny of cells exposed to either ZJU6 or Erianin Furthermore ZJU6 showed potent antiangiogenetic property and demonstrated radical scavenging capacity Due to its potent antiproliferative proapoptotic and antiangiogenic activities ZJU6 is an attractive chemotherapeutic agent to be developed

Keywords:

References

.
Search In Abstract Of Papers:
Other Papers In This Journal:
  1. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies
  2. Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial
  3. Cell cycle arrest through inhibition of tubulin polymerization by withaphysalin F, a bioactive compound isolated from Acnistus arborescens
  4. Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor
  5. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
  6. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
  7. Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries
  8. Publication biases and phase II trials investigating anticancer targeted therapies
  9. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients
  10. LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells
  11. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer
  12. Deactylase inhibition in myeloproliferative neoplasms
  13. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
  14. In vitro and in vivo antineoplastic and immunological effects of pterocarpanquinone LQB-118
  15. A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck
  16. Blackberry-induced hand-foot skin reaction to sunitinib
  17. A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer
  18. (+)-Episesamin exerts anti-neoplastic effects in human hepatocellular carcinoma cell lines via suppression of nuclear factor-kappa B and inhibition of MMP-9
  19. Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects
  20. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors
  21. Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics
  22. A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan
  23. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression
  24. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma
  25. Pretargeting of necrotic tumors with biotinylated hypericin using 123 I-labeled avidin: evaluation of a two-step strategy
  26. Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma
  27. Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil
  28. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
  29. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
  30. Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice
  31. Dose dependent inhibitory effect of dietary caraway on 1,2-dimethylhydrazine induced colonic aberrant crypt foci and bacterial enzyme activity in rats
  32. A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)
  33. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors
  34. The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells
  35. Phase 1 trial of Anvirzel™ in patients with refractory solid tumors
Search Result: